Investor Presentaiton
9
Investor presentation
Full year 2022
Novo NordiskⓇ
Obesity care sales grew by 84% in 2022 driven by both the US
and IO
NN sales and value market share
within Obesity care
Branded BAOM TRX in the US²
DKK billion
TRX count ('000s)
3%1
55%¹
84%¹
6
100%
70
60
LO
5
<
3
2
1
00
87%
50
50%
40
40
30
20
20
при
64
...
37
19
ONCE-WEEKLY
wegovy
semaglutide injection 2.4 mg
The US
Broad commercial formulary access
of more than 80%
All WegovyⓇ dose strengths made
available in the US in December 2022
International Operations
WegovyⓇ launched in Denmark and
Norway
10
0%
0
2020
2021
2022
June
2021
IO
NAO
-Market share (RHS)
Growth at CER
SaxendaⓇ
Branded AOM Market
Jan
2023
WegovyⓇ
•
Additional commercial launches
expected during 2023
1Annual growth at CER. Each TRx data points represents one week of data
2 IQVIA weekly, 13 Jan 2023
NAO: North America operations; IO: International operations; RHS: Right-hand side axis; Rx: Prescriptions; AOM: Anti-Obesity Medications (includes Wegovy®, SaxendaⓇ, Qsymia, Belviq and Contrave); Mg: milligram; CMO: Contract manufacturing organisation
Note: Sales growth at constant exchange rates. 63% volume growth for Global branded AOM market refers to MAT.View entire presentation